No stem-cell product for CKD has FDA approval as a primary therapeutic agent. Ongoing investigational protocols operate under IND and expanded-access pathways. REGEN-CKD (regenerative-medicine network) and similar consortia are enrolling patients globally. European regulatory frameworks permit compassionate-use access in some jurisdictions for advanced-stage patients with limited conventional alternatives.
Chronic kidney disease (CKD) reflects progressive nephron loss and functional decline, stemming from diverse primary insults (diabetes, hypertension, glomerulonephritis, polycystic kidney disease). Placental mesenchymal stem cells and their exosomes demonstrate anti-inflammatory and pro-regenerative properties relevant to CKD pathophysiology: they suppress macrophage infiltration into damaged glomeruli, inhibit fibrotic signalling pathways (TGF-β, SMAD2/3), and release growth factors that stabilise endothelial integrity. Eighty-eight registered trials and nine actively recruiting sites explore MSC infusion alongside conventional renin-angiotensin blockade and immunosuppression, particularly in early-to-intermediate stage disease where residual filtration capacity remains.
Съм ли кандидат? → · Chronic Kidney Disease: full overview → · Цена Хронична бъбречна болест → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка